NFKB1 and arthritic joint disease: It has been reported that systemic administration of NF-κB inhibitors can reverse inflammatory pain, reduce the expression of SP and CGRP in joints, and the expression of SP and CGRP in dorsal root ganglia (DRG) in animal models of arthritis (Ahmed et al., 2010, 2017).